Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO John Todd Koning Sells 37,500 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) CFO John Todd Koning sold 37,500 shares of the company’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $12.82, for a total transaction of $480,750.00. Following the completion of the transaction, the chief financial officer now directly owns 393,356 shares in the company, valued at approximately $5,042,823.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

John Todd Koning also recently made the following trade(s):

• On Friday, March 1st, John Todd Koning sold 121,601 shares of Alphatec stock. The stock was sold at an average price of $13.30, for a total transaction of $1,617,293.30.

Alphatec Stock Up 1.6 %

ATEC opened at $12.44 on Friday. The stock has a market cap of $1.72 billion, a PE ratio of -8.03 and a beta of 1.55. The company has a quick ratio of 1.99, a current ratio of 2.86 and a debt-to-equity ratio of 6.54. Alphatec Holdings, Inc. has a 52 week low of $8.66 and a 52 week high of $19.14. The business’s fifty day simple moving average is $13.69 and its 200 day simple moving average is $13.46.

Alphatec (NASDAQ:ATEC) last released its earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). The company had revenue of $138.00 million during the quarter, compared to analyst estimates of $131.90 million. During the same quarter in the previous year, the company posted ($0.33) earnings per share. The firm’s revenue was up 30.3% compared to the same quarter last year. As a group, research analysts expect that Alphatec Holdings, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Trading of Alphatec

Several institutional investors and hedge funds have recently bought and sold shares of ATEC. BluePath Capital Management LLC purchased a new stake in Alphatec in the third quarter worth about $29,000. RiverPark Advisors LLC purchased a new stake in Alphatec in the third quarter worth about $53,000. Provence Wealth Management Group purchased a new stake in Alphatec in the third quarter worth about $56,000. Van ECK Associates Corp bought a new position in shares of Alphatec during the third quarter valued at approximately $113,000. Finally, Tidemark LLC bought a new position in shares of Alphatec during the fourth quarter valued at approximately $137,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ATEC has been the topic of several research analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Alphatec in a report on Wednesday, March 20th. Wells Fargo & Company initiated coverage on shares of Alphatec in a report on Friday, February 9th. They issued an “overweight” rating and a $26.00 price target on the stock. Needham & Company LLC upped their price target on shares of Alphatec from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.63.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.